Add to a list

Inactive Instrument

RenovaCare, Inc. Stock Other OTC

RCAR

US75988J1060

Biotechnology & Medical Research

OTC Markets Traded

RenovaCare, Inc. is a clinical-stage biotechnology company. The Company is focused on developing autologous (self-donated) stem cell therapies for the regeneration of human organs. The Company through its wholly owned subsidiary, RenovaCare Sciences Corp. is focusing on the research, development and commercialization of autologous (using a patientâ€™s own cells) cellular therapies that can be used for medical and aesthetic applications. The Companyâ€™s CellMist System is a cell isolation procedure that enzymatically renders stem cells from the patientâ€™s own skin or other tissues. The resulting stem cell suspension is administered topically from the Companyâ€™s novel solution sprayer device (the SkinGun) as a cell therapy for wounds including burns to facilitate healing. Its SkinGun spray device is an advanced technology, using a gentle positive-pressure air stream to spray the CellMist Solution onto wounds.

Employees

Sector

Biotechnology & Medical Research

More about the company

-40%: Exceptional extension

SEIZE THE OFFER!

Market Cap	1.76M 1.53M 1.44M 1.32M 2.47M 168M 2.47M 17.31M 6.68M 85.72M 6.59M 6.45M 276M	P/E 2020	-25.6x	P/E 2021	-5.46x
Enterprise Value	-1.06M -929K -873K -797K -1.5M -102M -1.5M -10.48M -4.04M -51.89M -3.99M -3.9M -167M	EV / Sales 2020	-	EV / Sales 2021	-
Free-Float	100%	Yield 2020 *	-	Yield 2021	-

22-11-18	RenovaCare, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
22-08-12	RenovaCare, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI
22-05-12	RenovaCare, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
22-05-03	RenovaCare Announces Termination of StemCell Systems R&D Agreement	CI
22-03-30	RenovaCare, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
22-03-29	RenovaCare, Inc. Auditor Raises 'Going Concern' Doubt	CI
22-03-24	RenovaCare, Inc. Announces Management Changes	CI
22-03-24	RenovaCare, Inc. Announces CFO Changes	CI
22-03-24	RenovaCare, Inc. Announces CEO Changes	CI
22-02-03	RenovaCare, Inc. Enters into A Research and Collaboration Agreement with Histocell, S.L	CI
21-11-12	RenovaCare, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	CI
21-08-03	Renovacare, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	CI
21-07-22	RenovaCare, Inc Provides Update on Clinical Trial for the SkinGun™ and CellMist™ System for Wound Healing	CI

25-02-12	RenovaCare Inc. Provides Notice of Proposed Derivative Settlement to All Record Holders and Beneficial Owners of RenovaCare, Inc.	BU
22-11-18	RenovaCare: Q3 Earnings Snapshot	AQ
22-11-18	RENOVACARE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
22-08-12	RenovaCare: Q2 Earnings Snapshot	AQ
22-08-12	RENOVACARE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RENOVACARE, INC.	+0.19%	-6.62%	-	-	8.74K
WUXI APPTEC CO., LTD.	-0.07%	+7.14%	+53.95%	+111.00%	74.27B
ARGENX SE	-1.45%	-0.40%	+35.52%	+79.18%	61.21B
WUXI BIOLOGICS (CAYMAN) INC.	-0.09%	+5.33%	+33.16%	+20.37%	27.55B
INSMED INCORPORATED	-0.15%	+0.75%	-16.69%	+361.67%	26.38B
BIONTECH SE	+2.93%	+4.32%	+2.18%	-3.60%	25.34B
GENMAB A/S	+0.84%	+6.00%	+25.53%	-9.89%	20.84B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.18%	+4.99%	-5.82%	+520.40%	14.94B
PHARMAESSENTIA CORPORATION	+0.87%	-3.73%	+159.95%	+327.53%	15.17B
EXELIXIS, INC.	+1.63%	+2.20%	+46.92%	+170.72%	14.41B
Average	+0.34%	+3.17%	+37.19%	+175.26%	31.12B
Weighted average by Cap.	+0.03%	+3.44%	+36.62%	+136.02%

	2020	2021
Net sales	-	-
Net income	-9.55M -8.34M -7.84M -7.16M -13.43M -913M -13.43M -94.12M -36.32M -466M -35.86M -35.07M -1.5B	-4.47M -3.91M -3.67M -3.35M -6.29M -427M -6.29M -44.08M -17.01M -218M -16.79M -16.43M -704M
Net Debt	-7.33M -6.41M -6.02M -5.5M -10.32M -701M -10.32M -72.29M -27.89M -358M -27.54M -26.94M -1.15B	-2.82M -2.46M -2.32M -2.11M -3.97M -269M -3.97M -27.79M -10.72M -138M -10.59M -10.35M -444M

RenovaCare, Inc. Stock Other OTC

Stocks

RCAR

US75988J1060

Biotechnology & Medical Research

Valuation: RenovaCare, Inc.

Latest news: RenovaCare, Inc.

Press Releases: RenovaCare, Inc.

Quotes and Performance

Managers and Directors: RenovaCare, Inc.

Bio Therapeutic Drugs

Financials

Company Profile